Aspire Biopharma Holdings (ASBP) Other Non-Current Liabilities (2023 - 2025)

Aspire Biopharma Holdings (ASBP) has 3 years of Other Non-Current Liabilities data on file, last reported at $40954.0 in Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 91.8% year-over-year to $40954.0 in Q4 2025; TTM through Dec 2025 was $40954.0, a 91.8% decrease from a year earlier, with the FY2025 full-year figure at $40954.0, down 91.8% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $40954.0, down from $2.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ASBP reached as high as $2.0 million in Q2 2025 and fell as low as $40954.0 in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $743605.1 across 3 years, with a median of $450000.0 in 2024.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 350.08% in 2025 and fell as far as 91.8% in 2025.
• Year by year, Other Non-Current Liabilities stood at $155848.0 in 2023, then jumped by 220.32% to $499213.0 in 2024, then slumped by 91.8% to $40954.0 in 2025.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $40954.0 in Q4 2025, $2.0 million in Q2 2025, and $1.9 million in Q1 2025.